



## US Chronic Care has outperformed the market by a factor 2-3x and continues to take share





Source: Coloplast



### Chronic Care US - Challenger to leader

Continue to **expand product offering** and **win across patient pathway** in Ostomy Care

**Chronic Care US** Ostomy Care Continence Direct GROWTH Care Business **LEADERSHIP** Commercial execution

Grow our Direct business and establish Comfort Medical as the **go to dealer for US patients** 

Set the clinical standard of care for HCPs, expand digital offering and solutions, and build strong organisation and culture





Lead the **innovation** and **upgrade** 

market to hydrophilics in

Continence Care

## In Ostomy Care, innovation is the biggest growth driver and we continue to win across patient pathway





**Coloplast** 

# Coloplast continues to succeed in acute channel with Premier contract and large acute account wins

We have had major wins in the acute and post-acute care channel...









...And we are now the second largest player in the acute channel

Acute new patient discharged share

Hollister<sup>TM\*</sup>, Incorporated



#1

#2

Starting April, Coloplast was awarded access to Premier, one of the largest GPOs in the US

	Acute members <sup>1</sup>	Estimated Acute share <sup>2</sup>	Next award year	
Premier TM*	3,600	~25%	2023	
vizient.™	<sup>1*</sup> 7,500	~50%	2021	
Health Trust <sup>™</sup>	1,400	~15%	2023	

Source: Coloplast, GHX




<sup>1.</sup> Acute members can be part of more than one GPO

<sup>2.</sup> Coloplast estimates based on primary GPO affiliation

<sup>\*</sup> Third party trademarks are the property of their respective owner(s)
Coloplast Group – Ostomy Care / Continence Care / Wound & Skin Care / Urology Care

### In Continence Care, we continue to upgrade the market through product innovations and expanded sales force



We have launched significant innovation and SpeediCath Soft is our latest launch

SpeediCath® Flex Coude Pro



SpeediCath® Soft




Meanwhile, with the largest manufacturer sales force which we expanded in 18/19, we will continue to focus on key channels



### Introducing SpeediCath® Soft

### - a soft hydrophilic coated catheter with insertion grip





# We will take Comfort Medical to the next level with our Strive25 strategy

We have been executing our growth plan for Comfort Medical during the past couple years and have achieved double digit growth



Drive new patients demand



Improve **retention** of existing patients



Expand insurance coverage

Although still a relatively small player, our Strive 25 strategy aims to establish Comfort Medial as the go to dealer for US patients



Strengthen digital offering for a superior customer experience



Focus on patient support and education



## We are dedicated to making an impact by driving excellence in commercial execution

Strong commercial execution mindset runs across all functions in Coloplast







Set the clinical **standard of care for HCPs** through market development
and education

Expand digital solution and offerings to empower end-users and navigate post-COVID world

Build strong organisation and culture through talent development and emphasis on Inclusion & Diversity



<sup>\*</sup> Investment includes campaigns and related FTE costs

## Our US strategy positions us to outpace the market for years to come



Our ambition for US Chronic Care



Double digit profitable growth

+10%



#### Our mission

Making life easier for people with intimate healthcare needs

#### Our values

Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us

#### Our vision

Setting the global standard for listening and responding

